Chemotherapy may be better for certain patients with advanced lung cancer — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/04/140408162226.htm
source : http://www.sciencedaily.com/releases/2014/04/140408162226.htm
source : http://www.sciencedaily.com/releases/2014/03/140307111104.htm
source : http://www.sciencedaily.com/releases/2014/02/140226101821.htm
Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. …